Uterine serous carcinoma

Reassessing effectiveness of platinum-based adjuvant therapy

Lucia Tortorella, Carrie L. Langstraat, Amy L. Weaver, Michaela E. McGree, Jamie N Bakkum-Gamez, Sean Christopher Dowdy, William Arthur Cliby, Gary Keeney, Mark E. Sherman, Saravut (John) Weroha, Andrea Mariani, Karl C. Podratz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Two randomized trials failed to demonstrate efficacy of platinum-based chemotherapy (PbCT) for uterine serous carcinoma (USC). Our objective was to reassess the value of PbCT for patients with microscopic residuum (R0). Methods: Progression-free survival (PFS) after surgery was analyzed for 409 patients and correlated with adjuvant therapies: vaginal brachytherapy (VBRT), external beam radiotherapy (EBRT), PbCT, or combinations. Results: The estimated 5-year PFS for stage I (n = 209) USC was 65.1% for observation only; 90.7%, VBRT only; and 91.1%, PbCT ± VBRT (85% received VBRT); VBRT significantly (P =.004) impacted PFS, but the added value of PbCT remains uncertain. Of 58 stage IIIC, PbCT-treated patients (±EBRT), 5-year PFS was 33.9%; most failures had a vascular disseminated component. Median PFS for 72 stage IV, PbCT-treated patients was 18.6 months for R0; 8.0, R1 ≤ 1 cm residual disease; and 4.6, R2 > 1 cm (P =.008). The progression rate (PR) during 1 to 2 year follow-up for R0 was similar to PR during 0–1 year follow-up for R1 (P =.31), suggesting recurrences in patients with R0 disease before 2 years are likely platinum resistant. PRs during follow-up were nearly identical for R0 ≥ 2 years and R1 ≥ 1 year (P =.95), presumably showing limited numbers of platinum-sensitive tumors. Conclusions: A comparison of PR for patients treated with PbCT for stage IV R0 and R1 disease suggested that a 1-year lag interval precedes clinical recognition of PbCT refractory/resistant R0 disease. Most patients treated with PbCT who had microscopic residuum had recurrences within 2 years (across stages), emphasizing the need for more effective therapy.

Original languageEnglish (US)
JournalGynecologic Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Platinum
Carcinoma
Drug Therapy
Brachytherapy
Disease-Free Survival
Therapeutics
Radiotherapy
Recurrence
Combination Drug Therapy
Blood Vessels
Observation

Keywords

  • Platinum-based chemotherapy
  • Therapeutic efficacy
  • Uterine serous carcinoma

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Uterine serous carcinoma : Reassessing effectiveness of platinum-based adjuvant therapy. / Tortorella, Lucia; Langstraat, Carrie L.; Weaver, Amy L.; McGree, Michaela E.; Bakkum-Gamez, Jamie N; Dowdy, Sean Christopher; Cliby, William Arthur; Keeney, Gary; Sherman, Mark E.; Weroha, Saravut (John); Mariani, Andrea; Podratz, Karl C.

In: Gynecologic Oncology, 01.01.2018.

Research output: Contribution to journalArticle

@article{63f013939eb14dbf817f47283f6dc306,
title = "Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy",
abstract = "Objective: Two randomized trials failed to demonstrate efficacy of platinum-based chemotherapy (PbCT) for uterine serous carcinoma (USC). Our objective was to reassess the value of PbCT for patients with microscopic residuum (R0). Methods: Progression-free survival (PFS) after surgery was analyzed for 409 patients and correlated with adjuvant therapies: vaginal brachytherapy (VBRT), external beam radiotherapy (EBRT), PbCT, or combinations. Results: The estimated 5-year PFS for stage I (n = 209) USC was 65.1{\%} for observation only; 90.7{\%}, VBRT only; and 91.1{\%}, PbCT ± VBRT (85{\%} received VBRT); VBRT significantly (P =.004) impacted PFS, but the added value of PbCT remains uncertain. Of 58 stage IIIC, PbCT-treated patients (±EBRT), 5-year PFS was 33.9{\%}; most failures had a vascular disseminated component. Median PFS for 72 stage IV, PbCT-treated patients was 18.6 months for R0; 8.0, R1 ≤ 1 cm residual disease; and 4.6, R2 > 1 cm (P =.008). The progression rate (PR) during 1 to 2 year follow-up for R0 was similar to PR during 0–1 year follow-up for R1 (P =.31), suggesting recurrences in patients with R0 disease before 2 years are likely platinum resistant. PRs during follow-up were nearly identical for R0 ≥ 2 years and R1 ≥ 1 year (P =.95), presumably showing limited numbers of platinum-sensitive tumors. Conclusions: A comparison of PR for patients treated with PbCT for stage IV R0 and R1 disease suggested that a 1-year lag interval precedes clinical recognition of PbCT refractory/resistant R0 disease. Most patients treated with PbCT who had microscopic residuum had recurrences within 2 years (across stages), emphasizing the need for more effective therapy.",
keywords = "Platinum-based chemotherapy, Therapeutic efficacy, Uterine serous carcinoma",
author = "Lucia Tortorella and Langstraat, {Carrie L.} and Weaver, {Amy L.} and McGree, {Michaela E.} and Bakkum-Gamez, {Jamie N} and Dowdy, {Sean Christopher} and Cliby, {William Arthur} and Gary Keeney and Sherman, {Mark E.} and Weroha, {Saravut (John)} and Andrea Mariani and Podratz, {Karl C.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2018.02.022",
language = "English (US)",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Uterine serous carcinoma

T2 - Reassessing effectiveness of platinum-based adjuvant therapy

AU - Tortorella, Lucia

AU - Langstraat, Carrie L.

AU - Weaver, Amy L.

AU - McGree, Michaela E.

AU - Bakkum-Gamez, Jamie N

AU - Dowdy, Sean Christopher

AU - Cliby, William Arthur

AU - Keeney, Gary

AU - Sherman, Mark E.

AU - Weroha, Saravut (John)

AU - Mariani, Andrea

AU - Podratz, Karl C.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Two randomized trials failed to demonstrate efficacy of platinum-based chemotherapy (PbCT) for uterine serous carcinoma (USC). Our objective was to reassess the value of PbCT for patients with microscopic residuum (R0). Methods: Progression-free survival (PFS) after surgery was analyzed for 409 patients and correlated with adjuvant therapies: vaginal brachytherapy (VBRT), external beam radiotherapy (EBRT), PbCT, or combinations. Results: The estimated 5-year PFS for stage I (n = 209) USC was 65.1% for observation only; 90.7%, VBRT only; and 91.1%, PbCT ± VBRT (85% received VBRT); VBRT significantly (P =.004) impacted PFS, but the added value of PbCT remains uncertain. Of 58 stage IIIC, PbCT-treated patients (±EBRT), 5-year PFS was 33.9%; most failures had a vascular disseminated component. Median PFS for 72 stage IV, PbCT-treated patients was 18.6 months for R0; 8.0, R1 ≤ 1 cm residual disease; and 4.6, R2 > 1 cm (P =.008). The progression rate (PR) during 1 to 2 year follow-up for R0 was similar to PR during 0–1 year follow-up for R1 (P =.31), suggesting recurrences in patients with R0 disease before 2 years are likely platinum resistant. PRs during follow-up were nearly identical for R0 ≥ 2 years and R1 ≥ 1 year (P =.95), presumably showing limited numbers of platinum-sensitive tumors. Conclusions: A comparison of PR for patients treated with PbCT for stage IV R0 and R1 disease suggested that a 1-year lag interval precedes clinical recognition of PbCT refractory/resistant R0 disease. Most patients treated with PbCT who had microscopic residuum had recurrences within 2 years (across stages), emphasizing the need for more effective therapy.

AB - Objective: Two randomized trials failed to demonstrate efficacy of platinum-based chemotherapy (PbCT) for uterine serous carcinoma (USC). Our objective was to reassess the value of PbCT for patients with microscopic residuum (R0). Methods: Progression-free survival (PFS) after surgery was analyzed for 409 patients and correlated with adjuvant therapies: vaginal brachytherapy (VBRT), external beam radiotherapy (EBRT), PbCT, or combinations. Results: The estimated 5-year PFS for stage I (n = 209) USC was 65.1% for observation only; 90.7%, VBRT only; and 91.1%, PbCT ± VBRT (85% received VBRT); VBRT significantly (P =.004) impacted PFS, but the added value of PbCT remains uncertain. Of 58 stage IIIC, PbCT-treated patients (±EBRT), 5-year PFS was 33.9%; most failures had a vascular disseminated component. Median PFS for 72 stage IV, PbCT-treated patients was 18.6 months for R0; 8.0, R1 ≤ 1 cm residual disease; and 4.6, R2 > 1 cm (P =.008). The progression rate (PR) during 1 to 2 year follow-up for R0 was similar to PR during 0–1 year follow-up for R1 (P =.31), suggesting recurrences in patients with R0 disease before 2 years are likely platinum resistant. PRs during follow-up were nearly identical for R0 ≥ 2 years and R1 ≥ 1 year (P =.95), presumably showing limited numbers of platinum-sensitive tumors. Conclusions: A comparison of PR for patients treated with PbCT for stage IV R0 and R1 disease suggested that a 1-year lag interval precedes clinical recognition of PbCT refractory/resistant R0 disease. Most patients treated with PbCT who had microscopic residuum had recurrences within 2 years (across stages), emphasizing the need for more effective therapy.

KW - Platinum-based chemotherapy

KW - Therapeutic efficacy

KW - Uterine serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85043520811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043520811&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2018.02.022

DO - 10.1016/j.ygyno.2018.02.022

M3 - Article

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -